A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

GermFlare Announces Its Professional Handheld UVC Light Kills 99.99% of MRSA and P. Aeruginosa in Laboratory Testing

March 2, 2021

GermFlare, based in Denmark, today proudly reported its handheld UVC light called “GermFlare” to achieve greater than 99.99%, or 4log, inactivation of both Methicillin-Resistant Staphylococcus Aureus (MRSA) and Pseudomonas Aeruginosa (PA) in less than 5 seconds at a distance of 3.9 inches (10 cm).

Testing on the two bacteria strains was conducted by ALS Denmark A/S (part of ALS Laboratories), an accredited global certified laboratory.

Germflare, Uvc

The testing parameters were carefully selected to simulated how the effect of the GermFlare would be in the hands of its core user, the healthcare personnel at hospitals. GermFlare has previously been proven to inactivate SARS-CoV-2 at the Department of Immunology and Microbiology and Department of Infectious Diseases, Hvidovre Hospital, Denmark.

“Our focus is to provide a solution to the global Hospital Acquired Infection (HAI) problem and as MRSA is one of those bacteria our core users fight against every day, we are very pleased with the results.”

“We hope this test and the results can provide some comfort and confidence to the Healthcare personnel working in areas where there is an increased risk of contracting HAIs.”

“When the user starts to incorporate the use of GermFlare more in their daily routines the risk of being infected by any harmful pathogen decreases noticeable, and it could just be a quick 5-second treatment of any hotspots they touch. Even if the nurse forgets to use rubbing alcohol after they touched a door handle, they do not need to worry because if they used the GermFlare it would have killed the harmful pathogens and broken the chain of infection.” – states Flemming Dahlin, Chief Executive Officer, GermFlare.

 

SourceGermFlare
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy